Hematologic Malignancy
Virus-Related Lymphoma
CI-CAN-00001651Explore in graph →
Hematologic36 active trials1 evidence items
- NCIt
- C27699
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001651Explore in graph →
Clinical trials
225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (46)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05510908 | Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC | completed | — | 460 | AIDS Malignancy ConsortiumNETWORK | 2 | Aug 14, 2026 | clinicaltrials |
| NCT00006436 | EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection | completed | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2026 | clinicaltrials |
| NCT03264131 | BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma | completed | Phase 2 | 16 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT04975698 | HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903(BMTCTN1903) | completed | Phase 2 | 12 | Catherine BollardNIH | 1 | Jun 29, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06391814 | Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01) | completed | N/A | 1 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT02213913 | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 55 | University of ChicagoOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT02737046 | Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma | completed | Phase 2 | 15 | University of MiamiOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05784415 | Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell(CS22-03) | completed | — | 30 | AIDS Malignancy ConsortiumNETWORK | 1 | Feb 2, 2026 | clinicaltrials |
| NCT02588651 | A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) | completed | Phase 2 | 23 | Deepa JagadeeshOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT01771107 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 41 | National Cancer Institute (NCI)NIH | 2 | Aug 15, 2025 | clinicaltrials |
| NCT01184885 | A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy | completed | Early Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT02631746 | Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma | completed | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Mar 14, 2025 | clinicaltrials |
| NCT04102150 | Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma | completed | Phase 2 | 25 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT02595866 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | completed | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2024 | clinicaltrials |
| NCT02199184 | Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT01626664 | KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) | completed | Phase 2 | 71 | Kyowa Kirin, Inc.INDUSTRY | 6 | Apr 25, 2024 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT02168140 | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | completed | Phase 1 | 16 | Wake Forest University Health SciencesOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT01523223 | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies | completed | Phase 1 | 16 | Robert LowskyOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT01193842 | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 107 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2023 | clinicaltrials |
| NCT00924170 | Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia | completed | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 14, 2023 | clinicaltrials |
| NCT03546101 | Early Detection of Epstein-Barr Virus Related Disease. | completed | — | 1,527 | University of AarhusOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT01336920 | Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | completed | Phase 1 | 15 | University of NebraskaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT04185220 | Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome | completed | Phase 1 | 6 | National Cancer Institute (NCI)NIH | 1 | Jan 4, 2023 | clinicaltrials |
| NCT01775475 | Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma | completed | Phase 2 | 7 | AIDS Malignancy ConsortiumNETWORK | 2 | Oct 10, 2022 | clinicaltrials |
| NCT01261247 | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 41 | Mayo ClinicOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT02689453 | Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) | completed | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2022 | clinicaltrials |
| NCT00001563 | EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Jan 19, 2022 | clinicaltrials |
| NCT02973113 | Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)(PREVALE) | completed | Phase 1 | 8 | Baylor College of MedicineOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT02037256 | Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma | completed | N/A | 23 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 10, 2021 | clinicaltrials |
| NCT00536601 | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | completed | N/A | 174 | Roswell Park Cancer InstituteOTHER | 1 | Apr 22, 2021 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT02580552 | Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL | completed | Phase 1 | 66 | miRagen Therapeutics, Inc.INDUSTRY | 1 | Nov 23, 2020 | clinicaltrials |
| NCT01258998 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2020 | clinicaltrials |
| NCT01075321 | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 58 | Mayo ClinicOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02670616 | Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma | completed | Phase 2 | 24 | Samsung Medical CenterOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT00267865 | Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2020 | clinicaltrials |
| NCT00082888 | Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma | completed | Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT00040846 | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies | completed | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00014235 | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | completed | N/A | 160 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT01239875 | Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma | completed | Early Phase 1 | 16 | Mayo ClinicOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT00003196 | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma | completed | N/A | 63 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 27, 2019 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT02652715 | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | completed | N/A | 29 | Mayo ClinicOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT00856388 | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders | completed | N/A | 62 | Roswell Park Cancer InstituteOTHER | 1 | Nov 13, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Aug 14, 2026source: clinicaltrials